A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Latest Information Update: 01 Aug 2024
At a glance
- Drugs BMF-219 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Acronyms COVALENT-101
- Sponsors Biomea Fusion
- 31 Jul 2024 According to a Biomea Fusion media release, complete dose escalation portion of COVALENT-101 expected by year end 2024. (Two cohorts, CLL and DLBCL of COVALENT-101 have been discontinued due to insufficient enrollment.)
- 04 Mar 2024 Planned End Date changed from 1 Jan 2024 to 31 Mar 2025.
- 04 Mar 2024 Planned primary completion date changed from 1 Jan 2024 to 31 Dec 2024.